Ads
related to: monoclonal antibody treatment prostate cancer bone- Second Opinion
In Need of a Second Opinion?
Our Cancer Answer Line Can Help
- Prostate Cancer Treatment
Download our Prostate Cancer Guide
Find Prostate Cancer Treatments
- Virtual Second Opinions
Get Peace of Mind from Home.
Review Your Diagnosis & Treatment.
- Schedule an Appointment
Schedule an Appointment Today
Call our Cancer Answer Line
- Second Opinion
Search results
Results from the WOW.Com Content Network
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
Abituzumab is a humanized IgG2 monoclonal antibody (mAb) targeted at CD51 (an integrin) currently in development by Merck KGaA Darmstadt, Germany in an attempt to prevent bone lesion metastases in castration-resistant prostate cancer. [1] [2]
Denosumab, sold under the brand names Prolia among others, is a human monoclonal antibody used for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone. [11] [12] The most common side effects are joint and muscle pain in the arms or legs. [13]
It is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor with potential antineoplastic activity. Cixutumumab selectively binds to membrane-bound IGF-1R, thereby preventing the binding of the ligand IGF-1 and subsequent activation of PI3K / AKT signaling pathway.
Dr. Narayanan says that bone pain can also be a sign of prostate cancer recurrence in patients who have already had the disease. The link between prostate cancer and bone pain may be a surprising one.
The anti-RANKL antibody, denosumab, is also approved for use in cancer settings, and in those indications, it is branded as Xgeva. In both prostate and breast cancer, denosumab has been shown to reduce cancer treatment–induced bone loss. [21]
Ads
related to: monoclonal antibody treatment prostate cancer bone